Market Research

  Global Biosimulation Market accounted for US$ 2113.91 billion in 2020 and is estimated to be US$ 8969.47 billion by 2030 and is anticipated to register a CAGR of 15.4%. Biosimulation is a relatively new concept in the drug development industry, and it is based on defining biological systems in mathematical expressions, capturing biological constituents and their interactions, and modelling the behavior of a system in various scenarios.   Biosimulation employs a mathematical description of real-world processes within the human body, which is expressed as a series of interconnected differential equations.   Differential equations are used to express the interactions between elements, allowing simulation approaches to anticipate the system's behavior and the amounts of biological elements over time. The report  "   Global Biosimulation Market, By Product and Services (Software (Molecular Modeling and Simulation Software, PBPK Modeling and Simulation Software, PK/PD Modeling and

  The report  " Global Brain Implants Market, By Product Type (Deep Brain Stimulator, Spinal Cord Stimulator, and Others), By Application (Chronic Pain, Epilepsy, Parkinson’s Disease, and Others), and Region - Global Forecast to 2029"  Global brain implants market is projected to grow from US$ 4.7 billion in 2020 to US$ 13.3 billion by 2029. Factor driving the growth of the global brain implants market is increase in number of neurological disorders including Parkinson’s and Alzheimer’s diseases, depression, epilepsy, and essential tremor among all age groups across the globe. Also, rising investment from the government authorities and various healthcare organizations in emerging countries to improve overall healthcare infrastructure is propelling the target market growth. Furthermore, increasing awareness along with reduction in the cost of manufacturing of brain implants by new developments are some opportunities for the players to increase target market. Moreover, factors

  The report  " Global Sleep Apnea Devices Market, By Diagnostic Devices (Polysomnography Devices, Pulse Oximeters, and Actigraphy Devices), By Therapeutic Devices (Positive Airway Pressure (PAP) Devices, (Continuous Positive Airway Pressure (CPAP) Devices, and Bi-Level Positive Airway Pressure (BiPAP) Devices), Oxygen Devices (Oxygen Concentrators, Portable Oxygen Concentrators, and Liquid Portable Oxygen), Oral Appliances, Adaptive Servo Ventilation (ASV) Devices, and Masks and Accessories),  By  End User (Sleep Laboratories and Hospitals, and Home Care Settings/Individuals),   and  By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030” . Key Highlights: In September 2019, Philips unveils connected sleep apnea wearable NightBalance. In April 2017, In October 2017, Respicardia announced approval of Remed System from the U.S. FDA, for the treatment of moderate to severe central sleep apnea. The produc